文献速递白血病淋巴瘤

p53激活联合BCL-xL/BCL-2抑制作为高危和复发急性淋巴细胞白血病的治疗策略

Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2024-04-10

该研究在TP53野生型急性淋巴细胞白血病(ALL)的体外共培养模型(n=40)中证实MDM2拮抗剂idasanutlin具有强效抗白血病活性,并通过高通量筛选1971种FDA批准及临床在研化合物,确定BCL-xL/BCL-2抑制剂navitoclax为最佳联合伙伴。两药联合在体外对预后不良的原代白血病母细胞产生协同致死作用,并在两个极高危ALL异种移植模型中降低白血病负荷,其navitoclax血浆浓度与当代「低剂量」navitoclax临床试验中达到的浓度相当。

要点

  • idasanutlin在TP53野生型ALL体外共培养模型(n=40)中显示强效抗白血病活性。
  • 高通量筛选1971种化合物确定navitoclax为idasanutlin最有前景的联合伙伴。
  • idasanutlin-navitoclax联合在体外对预后不良原代白血病母细胞协同致死,并在两个极高危ALL异种移植模型中降低白血病负荷。

核心结论

  • idasanutlin与navitoclax联合在TP53野生型ALL的体外和异种移植模型中显示协同致死活性并降低白血病负荷,作者认为该联合值得考虑用于高危和复发ALL患者的治疗。

研究设计与样本

  • 研究采用TP53野生型ALL的体外共培养模型(n=40)评估idasanutlin的抗白血病活性。
  • 利用高通量联合筛选1971种FDA批准和临床在研化合物,寻找idasanutlin的最佳联合伙伴。
  • 在预后不良的原代衍生和原代患者白血病母细胞的体外共培养中评估联合效果,并在两个极高危ALL异种移植模型中评估白血病负荷。

主要发现

  • idasanutlin在TP53野生型ALL体外共培养模型(n=40)中显示强效抗白血病活性。
  • 高通量筛选1971种FDA批准和临床在研化合物,确定BCL-xL/BCL-2抑制剂navitoclax为最有前景的idasanutlin联合伙伴。
  • idasanutlin-navitoclax联合对预后不良的原代衍生和原代患者白血病母细胞在体外共培养中协同致死。
  • 联合治疗在两个极高危ALL异种移植模型中降低白血病负荷,所用药物浓度在患者中可安全达到,navitoclax血浆浓度与当代「低剂量」navitoclax临床试验中达到的浓度相当。
  • 联合治疗优先激活细胞死亡而非G1细胞周期阻滞,机制上涉及MCL-1结合促凋亡增敏蛋白NOXA。

临床怎么用

  • 作者认为,两种独立处于ALL临床评估中的临床阶段化合物的联合具有高度临床相关性,值得考虑用于高危和复发ALL患者的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Due to the rarity of TP53 mutations in acute lymphoblastic leukemia (ALL), p53 re-activation by antagonism of the p53-MDM2 interaction represents a potential therapeutic strategy for the majority of ALL. Here, we demonstrate the potent antileukemic activity of the MDM2 antagonist idasanutlin in high-risk and relapsed ex vivo coculture models of TP53 wildtype ALL (n = 40). Insufficient clinical responses to monotherapy MDM2 inhibitors in other cancers prompted us to explore optimal drugs for combination therapy. Utilizing high-throughput combination screening of 1971 FDA-approved and clinically advanced compounds, we identified BCL-xL/BCL-2 inhibitor navitoclax as the most promising idasanutlin combination partner. The idasanutlin-navitoclax combination was synergistically lethal to prognostically-poor, primary-derived and primary patient blasts in ex vivo coculture, and reduced leukemia burden in two very high-risk ALL xenograft models at drug concentrations safely attained in patients; in fact, the navitoclax plasma concentrations were equivalent to those attained in contemporary "low-dose" navitoclax clinical trials. We demonstrate a preferential engagement of cell death over G1 cell cycle arrest, mechanistically implicating MCL-1-binding pro-apoptotic sensitizer NOXA. The proposed combination of two clinical-stage compounds independently under clinical evaluation for ALL is of high clinical relevance and warrants consideration for the treatment of patients with high-risk and relapsed ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bell HL, Blair HJ, Jepson Gosling SJ, et al. Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia. 2024. PMID: 38600316. doi:10.1038/s41375-024-02241-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。